UniQure’s Mixed Data In Huntington’s May Slow Firm’s Momentum

 
• By Joseph Haas

UniQure’s Phase I/II interim readout in Huntington’s disease showed improvements on functional and clinical measures, but mixed results on a pair of biomarkers.

Confusion
UniQure's investors aren't sure what to make of the firm's new Huntington's data • Source: Shutterstock

More from Clinical Trials

More from R&D